4q4f: Difference between revisions
No edit summary |
No edit summary |
||
(2 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
==Crystal structure of LIMP-2 (space group C2)== | ==Crystal structure of LIMP-2 (space group C2)== | ||
<StructureSection load='4q4f' size='340' side='right' caption='[[4q4f]], [[Resolution|resolution]] 2.80Å' scene=''> | <StructureSection load='4q4f' size='340' side='right'caption='[[4q4f]], [[Resolution|resolution]] 2.80Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4q4f]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Q4F OCA]. For a <b>guided tour on the structure components</b> use [ | <table><tr><td colspan='2'>[[4q4f]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Q4F OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4Q4F FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=M6D:6-O-PHOSPHONO-BETA-D-MANNOPYRANOSE'>M6D</scene>, <scene name='pdbligand= | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.8Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=M6D:6-O-PHOSPHONO-BETA-D-MANNOPYRANOSE'>M6D</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4q4f FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4q4f OCA], [https://pdbe.org/4q4f PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4q4f RCSB], [https://www.ebi.ac.uk/pdbsum/4q4f PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4q4f ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Disease == | == Disease == | ||
[ | [https://www.uniprot.org/uniprot/SCRB2_HUMAN SCRB2_HUMAN] Unverricht-Lundborg disease;Gaucher disease type 1;Action myoclonus - renal failure syndrome. The disease is caused by mutations affecting the gene represented in this entry. Genetic variants in SCARB2 can act as modifier of the phenotypic expression and severity of Gaucher disease. | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/SCRB2_HUMAN SCRB2_HUMAN] Acts as a lysosomal receptor for glucosylceramidase (GBA) targeting.<ref>PMID:18022370</ref> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 25: | Line 25: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: | [[Category: Large Structures]] | ||
[[Category: | [[Category: Fry LE]] | ||
[[Category: | [[Category: Padilla-Parra S]] | ||
[[Category: Ren J]] | |||
[[Category: Stuart DI]] | |||
[[Category: | [[Category: Zhao Y]] | ||
[[Category: | |||
[[Category: | |||